SUMO2 deletion changes chromatin accessibility and enhances cytotoxic T cell activation and tumor infiltration
Science Advances · 2026
DOI: 10.1126/sciadv.aef2217 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Mohottige D Neranjan Tharuka und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of California, San Diego, La Jolla, CA 92037, USA. Hauptthemen laut MEDLINE: Lymphocyte Activation, T-Lymphocytes, Cytotoxic, Small Ubiquitin-Related Modifier Proteins, Chromatin. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, DOD.
Abstract (Originalsprache)
Cytotoxic T cells [cytotoxic lymphocytes (CTLs)] are crucial for adaptive immunity leading to prolonged survival and potential cures for cancer. Recent clinical data have shown that pharmacological inhibition modifies the tumor microenvironment (TME) and activates CTLs, although the mechanism is not well described. In this study, we found that T cell–specific knockout (KO) of the most prevalent SUMO paralog, Sumo2 / SUMO2 , in both mouse and human CD8 + T cells significantly enhanced CD8 + T cell activation without enhanced IFN-I (type I interferon)–responsive genes in vitro but increased chromatin accessibility at enhancer regions for AP-1 (activating protein 1) family members, including BATF and JunB, which are known to promote T cell activation and proliferation. Using antigen-specific OT1 and CAR (chimeric antigen receptor) T cell models, we found that Sumo2 KO CD8 + T cells had significantly higher tumor infiltration, as revealed by flow cytometry, immunofluorescence staining, and single-nucleus RNA sequencing (snRNA-seq), and conferred greater tumor growth inhibition than wild-type control T cells. snRNA-seq also revealed that Sumo2 KO in CD8 + T cells increased the expression of TRAIL (tumor necrosis factor–related apoptosis-inducing ligand) in vivo and activated the antitumor immune microenvironment, likely through cell-cell interaction involving more activated CTLs. These findings elucidate a novel mechanism by which SUMOylation controls CTL activation and tumor infiltration that activate antitumor immunity in the TME. SUMO2 KO can also be a potential strategy to enhance adoptive T cell therapies for solid tumors by enhancing their activation, tumor infiltration and ability to modulate the TME.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of California, San Diego, La Jolla, CA 92037, USA.
- Department of Bioengineering, University of California, San Diego, La Jolla, CA 92037, USA.
- Department of Chemistry, University of California, San Diego, La Jolla, CA 92037, USA.
- New York Genome Institute, New York, NY 10013, USA.
- La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
- Salk Institute for Biological Sciences, La Jolla, CA 92037, USA.
ORCID-Profile: Mohottige D Neranjan Tharuka, Dai-Hua Chen, Tianchen Ren, Yixuan Kuang, Shih-Ting Huang, Nikhil Chilakapati, Bing Ren, Stephen P Schoenberger, Ye Zheng, Yuan Chen
Förderung
- NCI NIH HHS
- NIH HHS
- DOD
- national institute of health
Zitieren
APA
Neranjan Tharuka, M. D., Chen, D. H., Amaral, M. L. J., Ren, T., Kuang, Y., Huang, S. T., Chilakapati, N., Ren, B., Schoenberger, S. P., Zheng, Y., & Chen, Y. (2026). SUMO2 deletion changes chromatin accessibility and enhances cytotoxic T cell activation and tumor infiltration. Science Advances. https://doi.org/10.1126/sciadv.aef2217
Vancouver
Neranjan Tharuka MD, Chen DH, Amaral MLJ, Ren T, Kuang Y, Huang ST, et al. SUMO2 deletion changes chromatin accessibility and enhances cytotoxic T cell activation and tumor infiltration. Science Advances. 2026. doi:10.1126/sciadv.aef2217
BibTeX
@article{NeranjanTharuka2026,
author = {Neranjan Tharuka, Mohottige D and Chen, Dai-Hua and Amaral, Maria Luisa Jurgensen and Ren, Tianchen and Kuang, Yixuan and Huang, Shih-Ting and Chilakapati, Nikhil and Ren, Bing and Schoenberger, Stephen P and Zheng, Ye and Chen, Yuan},
title = {SUMO2 deletion changes chromatin accessibility and enhances cytotoxic T cell activation and tumor infiltration},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aef2217}
}
EUVIMED